Condition: Acute Leukemia · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California Irvine Medical Center | Orange, California, United States | Completed |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation | Indianapolis, Indiana, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Completed |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Completed |
| Start Midwest | Grand Rapids, Michigan, United States | Recruiting |
| University of New Mexico | Albuquerque, New Mexico, United States | Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04811560